Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are: EVX-01, EVX-03, and EVX-02, which are vaccine candidates being developed for the treatment of various solid cancers. In addition, the company is developing EVX-B1, EVX-B2, EVX-B3, EVX-V1, and multiple other vaccine candidates for various infectious diseases, such as cytomegalovirus, N.gonorrhoeae, bacterial pathogens, and others.
This company has not yet paid dividends.